What Diclofenac-Еskom Treats: Main Uses and Benefits

Diclofenac-Еskom is a medication belonging to the group of non-steroidal anti-inflammatory drugs (NSAIDs). It is primarily used to manage pain and reduce inflammation across a variety of medical conditions. By inhibiting specific enzymes in the body that produce prostaglandins—chemicals responsible for signaling pain and swelling—the medication helps improve physical comfort and mobility.

Therapeutic Indications

The medication is used to address several acute and chronic conditions characterized by pain and inflammatory processes:

• Inflammatory Rheumatic Diseases: It is commonly utilized to manage symptoms of rheumatoid arthritis, ankylosing spondylitis, and osteoarthritis. It helps reduce joint swelling and morning stiffness.
• Degenerative Joint Conditions: It provides relief for painful flares associated with joint degeneration and spinal syndromes.
• Soft Tissue Disorders: The treatment is effective for extra-articular rheumatism, including conditions such as bursitis, tendinitis, and tenosynovitis.
• Post-Traumatic and Post-Operative Pain: It is used to manage pain, inflammation, and edema (swelling) following injuries or surgical interventions.
• Acute Gout: It is indicated for the relief of pain during acute attacks of gouty arthritis.

Primary Benefits

The clinical application of Diclofenac-Еskom offers several therapeutic benefits for patients managing inflammatory pain:

• Reduction of Inflammation: The medication directly targets the physiological processes that cause tissue swelling and heat at the site of injury or disease.
• Analgesic Effect: It provides significant relief from various types of pain, ranging from mild to moderate intensity.
• Improved Mobility: By reducing joint stiffness and discomfort, the medication helps patients maintain or regain better functional movement and perform daily activities more easily.
• Rapid Action: In certain formulations, the active substance is absorbed quickly to provide timely relief during acute pain episodes.

Eligibility for Diclofenac-Еskom

Diclofenac-Еskom (systemic diclofenac sodium) is generally approved for use in the adult population (18 years and older). Safety and efficacy have not been established for the injectable formulation in the pediatric population.

Contraindications and Non-Eligibility

Regulatory documents strictly prohibit the use of this medicine in patients with specific conditions, regardless of age:

• Known hypersensitivity to diclofenac or any other Non-Steroidal Anti-Inflammatory Drug (NSAID), including a history of asthma, hives, or allergic-type reactions after taking aspirin.
• Established congestive heart failure (NYHA Class II-IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease.
• Active gastrointestinal (GI) bleeding, ulceration, or a history of recurrent peptic ulcers.
• Severe renal impairment or severe hepatic failure.
• The third trimester of pregnancy (starting at 30 weeks gestation) and in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Conditional Use and Restrictions

Use requires caution and close monitoring in patients who are elderly, have mild to moderate renal or hepatic impairment, or have significant cardiovascular risk factors (e.g., hypertension). Use is not recommended for women who are attempting to conceive or who are breastfeeding.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Diclofenac-Eskom (Diclofenac sodium injection) as stated in government regulatory sources. These interactions are classified by their resulting effect on drug exposure or pharmacodynamic risk.

Contraindicated Combinations

Co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors and aspirin at analgesic doses, is strictly prohibited due to an increased risk of serious gastrointestinal adverse events, such as bleeding and ulceration. The medicine is also contraindicated for managing pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Exposure-Altering Interactions

Interacting Medicine	Official Outcome
CYP2C9 Inhibitors (e.g., Voriconazole)	Increased systemic exposure (AUC/Cmax) of diclofenac.
Lithium, Digoxin, Methotrexate	Increased plasma concentration of the co-administered drug.

Pharmacodynamic Risk and Diminishment

• Increased Bleeding Risk: Use with anticoagulants, antiplatelet agents, SSRIs, SNRIs, or systemic corticosteroids is associated with an increased risk of serious gastrointestinal bleeding.
• Antihypertensive Diminishment: Diclofenac may diminish the therapeutic effects of blood pressure medications, including ACE inhibitors and diuretics. In elderly, volume-depleted, or renally impaired patients, this combination is noted to pose an increased risk of renal function deterioration.
• Substance Caution: Co-use with alcohol or tobacco is documented to enhance the risk of serious gastrointestinal adverse events.

How Diclofenac-Eskom Works: Mechanism of Action

Diclofenac-Eskom operates through a multifaceted pharmacodynamic profile, initiated by the competitive inhibition of the Cyclooxygenase ( COX) enzymes, specifically COX-1 and COX-2. This interaction interrupts the arachidonic acid cascade, reducing the synthesis of inflammatory mediators, such as Prostaglandin E2 ( PGE2). The suppression of PGE2 is key to mitigating peripheral nociceptor sensitization and decreasing localized vascular permeability.

Beyond this primary action, the molecule engages a non-COX-dependent mechanism by modulating neuronal membrane excitability. It achieves this by directly blocking voltage-dependent sodium channels ( Nav channels) on sensory neurons. This dampens the electrical excitability of pain-transmitting fibers, limiting their ability to generate and propagate action potentials toward the central nervous system.

A central physiological effect involves COX-2 inhibition within the hypothalamus. By reducing pyrogenic PGE2 concentration in this area, the mechanism assists in resetting the body's elevated thermal set-point, initiating heat loss mechanisms contributing to the adjustment of core body temperature.

How to Use Diclofenac-Еskom — Administration Guidelines

This section outlines the instructions for the proper use and administration of diclofenac injection. Adherence to these guidelines defines the standardized approach for using the medicine.

---

Administration Scope

Diclofenac-Еskom is administered via parenteral route, specifically as an Intramuscular (IM) injection or as an Intravenous (IV) infusion.

• Dosing Requirements: The prescribed dose must be the lowest effective dose for the shortest duration possible. The total maximum daily dose across all routes is 150 mg.
• Duration of Use: Parenteral treatment (IM/IV) should not exceed two days. Continuation of therapy, if necessary, must transition to an oral or suppository form.

Procedural Instructions

Administration Method	Procedural Steps and Rules
Intramuscular (IM)	Administer one 75 mg ampoule daily as a deep intragluteal injection into the upper outer quadrant. In severe cases, a second 75 mg dose may be given, but must be injected into the opposite buttock, ensuring total daily dose does not exceed 150 mg.
Intravenous (IV)	IV bolus injection is not permitted. The drug must be administered as a slow infusion. Prior to adding the diclofenac ampoule, the infusion solution (0.9% sodium chloride or 5% glucose solution) must be diluted and buffered with sodium bicarbonate solution (0.5 mL of 8.4% or 1 mL of 4.2%).

Special Conditions

• Post-Administration Observation: Due to the risk of hypersensitivity reactions, an observation period of at least one hour must be maintained following IM or IV administration.
• Age Restriction: This medicine is not recommended for use in children and adolescents (generally under 18 years of age).
• Missed Dose: For this acute regimen, the maximum daily limit must be strictly adhered to.

Recent Clinical Evidence

Phase 3 Trial Data

Research has explored whether the drug may be associated with a reduction in the severity of chronic, non-malignant pain. Several Phase 3 trials included an assessment of changes in reported pain levels. Studies examined whether the drug's administration was associated with changes in the frequency of flare-ups, and long-term data collection examined the potential association between the combination of treatments and patient prognosis.

---

Comparative Studies and Formulation

This treatment has been studied in comparison with other existing therapies, with findings published in peer-reviewed journals. Comparative trials focus on assessing different outcomes, including patient-reported pain intensity and functional measures. Studies have also examined different dosing approaches.

---

Biological Pathway

Research explored the proposed biological pathway of the drug’s action. This involves the function as a non-steroidal anti-inflammatory drug (NSAID), which primarily reduces the production of substances in the body that signal pain and inflammation. Studies included an assessment of the timeframe during which changes in reported symptoms were recorded.

---

Specific Populations and Effects

Clinical trials have included participants with various underlying health factors to assess effects in specific groups. Trial data included participants with mild liver impairment for assessment of effects in this group. Specific trials evaluated effects in participants with a history of cardiovascular events. Additional research included an examination of effects in an older adult population, and data from a six-month observational study provided initial information on long-term effects.

Key Studies & References

1. NICE Guideline NG193: Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain
2. Clinical Trial Registry: Efficacy and Safety Study of Diclofenac in Chronic Non-Malignant Pain (Placeholder for a specific Phase 3 trial)

Common questions about Diclofenac-Еskom (FAQ)

---

Q: How quickly should I expect Diclofenac-Eskom to start working for pain?

A: Diclofenac-Eskom is a solution for injection, and this administration route is associated with rapid absorption into the body. This is associated with a rapid onset of effect. For related formulations, absorption is noted to begin shortly after administration.

---

Q: How long does the pain relief from Diclofenac-Eskom typically last?

A: The medicine is eliminated with a half-life of approximately 2 hours, meaning half of the dose is cleared in that time. However, analgesic effects have been noted in research to range up to approximately 8 hours.

---

Q: Is Diclofenac-Eskom available as both a tablet and a topical gel?

A: While the active ingredient, diclofenac, is available in multiple formulations—including oral tablets and topical gels—the product Diclofenac-Eskom is specifically defined as a solution for injection (ampoules). This formulation is intended to deliver the medicine throughout the body via injection routes.

---

Q: How long does Diclofenac-Eskom stay in your system?

A: The medicine is eliminated with a half-life of approximately 2 hours, meaning half of the dose is cleared in that time. Diclofenac is primarily cleared by the kidneys and liver.

---

Q: Why is Diclofenac-Eskom sometimes prescribed for arthritis pain?

A: Diclofenac is an NSAID that is officially indicated for relieving the signs and symptoms of inflammatory conditions. This includes chronic conditions such as osteoarthritis and rheumatoid arthritis, where its anti-inflammatory action is used to help manage pain and discomfort.

---

Q: Why do some doctors prescribe Diclofenac-Eskom for gout attacks?

A: Official guidelines indicate that diclofenac is used for treating pain and inflammatory diseases. This includes conditions like acute gout attacks, as it is indicated for the treatment of pain and inflammation related to these conditions.

---

Q: Can Diclofenac-Eskom be used for pain related to dental procedures?

A: Official documents indicate that diclofenac is approved for the short-term management of painful conditions where swelling is a factor. This includes pain that may follow dental procedures.

---

Q: Is Diclofenac-Eskom considered a strong painkiller?

A: Diclofenac is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). It is recognized as an effective agent used for controlling pain and inflammation.

---

Q: Is it normal to feel a bit nauseous after taking Diclofenac-Eskom?

A: Nausea is a commonly reported symptom of diclofenac use. Official regulatory documents list nausea as an adverse reaction with an incidence greater than 1%.

---

Q: Can using Diclofenac-Eskom cause skin sensitivity to the sun?

A: Official product information states that an increased sensitivity of the skin to sunlight (photosensitivity) is a reported adverse reaction. Patients are advised to be aware of this potential side effect.

---

Q: Why do some people experience ringing in their ears with Diclofenac-Eskom?

A: Ringing or buzzing in the ears (tinnitus) has been reported as an adverse effect of diclofenac. This symptom may be related to the drug's effect on the nervous system.

---

Q: What evidence supports the use of Diclofenac-Eskom for menstrual cramps?

A: Regulatory information indicates that diclofenac is indicated for the symptomatic treatment of primary dysmenorrhoea, which is the medical term for menstrual cramps.

---

Q: Is Diclofenac-Eskom an effective treatment for back pain or sciatica?

A: Official medical guidelines indicate that the medicine is indicated for the treatment of moderate pain due to inflammation. This includes conditions like acute sciatic neuralgia (sciatica).

---

Q: Are there different strengths of Diclofenac-Eskom tablets available?

A: While Diclofenac-Eskom specifically refers to the 75 mg injectable solution, the active ingredient, diclofenac sodium, is available in different strengths for oral formulations. Common tablet strengths include 25 mg, 50 mg, and 75 mg.

---

Q: Is it okay to drive or operate machinery after taking Diclofenac-Eskom?

A: Diclofenac is known to potentially cause side effects that affect the central nervous system, such as dizziness, tiredness, sleepiness, or visual disturbances. If a person experiences these symptoms, operating machinery or driving is generally not recommended.

---

Q: What should I do if I accidentally take more Diclofenac-Eskom than intended?

A: Overdose symptoms can include vomiting, stomach bleeding, diarrhea, dizziness, ringing in the ears, or convulsions. Symptoms of overdose require immediate medical attention.

---

Q: Are there any specific foods or drinks that should be avoided when using this medication?

A: Co-use of alcohol is documented to enhance the risk of serious gastrointestinal side effects and is generally not recommended. Food does not significantly alter the absorption of the medicine.

---

Q: Are there any long-term health concerns associated with using Diclofenac-Eskom?

A: The treatment is primarily indicated for short-term use. Official warnings state that long-term use, especially at high doses, is associated with an increased risk of serious cardiovascular events (e.g., heart attack, stroke) and major gastrointestinal issues.

---

Q: Is it true that Diclofenac-Eskom can be used for migraine headaches?

A: Regulatory labeling indicates that diclofenac is approved for the short-term treatment of acute migraine attacks, which includes migraines that occur with or without an aura.

---

Q: Is Diclofenac-Eskom the same kind of drug as ibuprofen or naproxen?

A: Diclofenac, ibuprofen, and naproxen all belong to the same pharmacological class: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). They share a similar mechanism of action, working to reduce pain and inflammation.

---

Q: Does Diclofenac-Eskom interact with common over-the-counter pain relievers?

A: Co-administration of diclofenac with other NSAIDs, including aspirin, is generally contraindicated. This combination carries a significantly increased risk of serious gastrointestinal adverse events, such as bleeding and ulceration.

---

Q: Does Diclofenac-Eskom have a potential for interaction with blood thinners?

A: Official warnings indicate a risk of interaction with anticoagulants (commonly called blood thinners). Using these medicines together is associated with an increased risk of serious gastrointestinal bleeding.

---

Q: Does alcohol consumption change how Diclofenac-Eskom works?

A: Alcohol consumption does not significantly change how the body absorbs diclofenac. However, co-use is generally not recommended as it is documented to enhance the risk of serious gastrointestinal side effects.

Official Storage and Disposal Requirements

The storage and disposal of Diclofenac injection must strictly follow the conditions specified in regulatory labeling to maintain the product's quality and ensure environmental safety.

Requirement Category	Official Regulatory Statement
Storage Temperature	Store below 25 C (77 F), at controlled room temperature.
Protection	Keep ampoules in the original outer carton and protect from light.
Prohibited Environment	Do not freeze the solution for injection.
Stability after Opening	The content of an opened ampoule is for immediate use; discard any unused portion.
Child-Safety	Keep out of the sight and reach of children and pets.
Disposal Instructions	Dispose of unused or expired medicine in accordance with local and national regulations for pharmaceutical waste, avoiding household waste and wastewater.

---

These instructions collectively establish the required environment for the product, preventing degradation from light and temperature extremes, and mandate strict compliance with pharmaceutical waste procedures for safe discarding.